Clinical relevance of cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients

Lin, Kuan‐Yin; Hung, Chien‐Ching

doi:10.1097/qad.0000000000000835

Cited by 5 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…El metabolismo de zidovudina (AZT) y abacavir (ABC) es por glucuronidación; por ello, sus concentraciones pueden verse afectados por medicamentos que utilicen esta vía. Por su parte, lamivudina (3TC), emtricitabina (FTC) y tenofovir (TDF) se eliminan principalmente por vía renal, mediante filtración glomerular en 86,0, 70,0 y 80,0%, respectivamente 16 , y por secreción tubular activa 16 . Estos medicamentos deben ajustarse en pacientes con enfermedad renal 11,16 y evitar su prescripción en conjunto con otros fármacos nefrotóxicos, debido a que se pueden acumular éstos, especialmente TDF, en los túbulos proximales renales 11 .…”

Section: Discussionunclassified

Relevancia clínica de las interacciones medicamentosas en pacientes infectados con el virus de la inmunodeficiencia humana: actualización 2015-2017

Pino-Marín

et al. 2019

Rev. chil. infectol.

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Relevancia clínica de las interacciones medicamentosas en pacientes infectados con el virus de la inmunodeficiencia humana: actualización 2015-2017

Pino-Marín

et al. 2019

Rev. chil. infectol.

View full text Add to dashboard Cite

show abstract

“…Herbst et al [118] suggested that the detection of HPP1 methylation in cfDNA might be used as a prognostic marker and an early marker to identify patients who will likely benefit from a combination of chemotherapy and bevacizumab. However, the methylation status of cfDNA and its application to detect MRD and response to treatment are studied less intensively [119,120].…”

Section: Role Of Ctdna In Management Of Colorectal Cancermentioning

confidence: 99%

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer

Arisi

Dotan

Fernandez

2022

IJMS

View full text Add to dashboard Cite

Circulating tumor DNA (ctDNA) is a component of cell-free DNA (cfDNA) that is shed by malignant tumors into the bloodstream and other bodily fluids. ctDNA can comprise up to 10% of a patient’s cfDNA depending on their tumor type and burden. The short half-life of ctDNA ensures that its detection captures tumor burden in real-time and offers a non-invasive method of repeatedly evaluating the genomic profile of a patient’s tumor. A challenge in ctDNA detection includes clonal hematopoiesis of indeterminate potential (CHIP), which can be distinguished from tumor variants using a paired whole-blood control. Most assays for ctDNA quantification rely on measurements of somatic variant allele frequency (VAF), which is a mutation-dependent method. Patients with certain types of solid tumors, including colorectal cancer (CRC), can have levels of cfDNA 50 times higher than healthy patients. ctDNA undergoes a precipitous drop shortly after tumor resection and therapy, and rising levels can foreshadow radiologic recurrence on the order of months. The amount of tumor bulk required for ctDNA detection is lower than that for computed tomography (CT) scan detection, with ctDNA detection preceding radiologic recurrence in many cases. cfDNA/ctDNA can be used for tumor molecular profiling to identify resistance mutations when tumor biopsy is not available, to detect minimal residual disease (MRD), to monitor therapy response, and for the detection of tumor relapse. Although ctDNA is not yet implemented in clinical practice, studies are ongoing to define the appropriate way to use it as a tool in the clinic. In this review article, we examine the general aspects of ctDNA, its status as a biomarker, and its role in the management of early (II–III) and late (IV; mCRC) stage colorectal cancer (CRC).

show abstract

“…azetazolamide, forusemide, celecoxib, thiazide diuretics, sumatriptan, sotalol, probenacid) do not contain the structural region known to cause the allergic response (i.e., N1 heterocyclic ring; an N-containing ring attached to the N1 nitrogen of the sulfonamide group and arylamine group at the N4 position). Although early reports questioned the potential for cross-reactivity between TMP-SMX and darunavir [249,251,252], authors have noted an absence of TMP-SMX allergy history in those with darunavir hypersensitivity [253–255]. Notably patients with a history of sulfa antimicrobial allergy were not excluded from darunavir clinical trials.…”

Section: Cross Reactivity In T-cell-mediated Reactionsmentioning

confidence: 99%

Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity

Konvinse

Phillips

White

et al. 2016

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Antimicrobials are a leading cause of severe T-cell-mediated adverse drug reactions (ADRs). The purpose of this review is to address the current understanding of antimicrobial cross-reactivity and the ready availability of and evidence for in vitro, in vivo and ex vivo diagnostics for T-cell-mediated ADRs. Recent findings Recent literature has evaluated the efficacy of traditional antibiotic allergy management including patch testing, skin prick testing, intradermal testing and oral challenge. While patch and intradermal testing are specific for the diagnosis of immune-mediated (IM) ADRs, they suffer from drug-specific limitations in sensitivity. The use of ex vivo diagnostics, especially ELISpot has been highlighted as a promising new approach to assigning causality. Knowledge of true rates of antimicrobial cross-reactivity aids empirical antibiotic choice in the setting of previous IM-ADRs. Summary In an era of increasing antimicrobial resistance and use of broad-spectrum antimicrobial therapy, ensuring patients are assigned the correct “allergy label” is essential. Re-exposure to implicated antimicrobials, especially in the setting of severe adverse cutaneous reaction is associated with significant morbidity and mortality. The process through which an antibiotic label gets assigned, acted on and maintained is still imprecise. Predicting T-cell-mediated ADRs via personalised approaches, including HLA-typing may pave future pathways to safer antimicrobial prescribing guidelines.

show abstract

Clinical relevance of cross-reactivity between darunavir and trimethoprim-sulfamethoxazole in HIV-infected patients

Cited by 5 publications

References 10 publications

Relevancia clínica de las interacciones medicamentosas en pacientes infectados con el virus de la inmunodeficiencia humana: actualización 2015-2017

Relevancia clínica de las interacciones medicamentosas en pacientes infectados con el virus de la inmunodeficiencia humana: actualización 2015-2017

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer

Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity

Contact Info

Product

Resources

About